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Abstract
Background: The Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP) Study aims to examine whether a
polypill-based strategy (using a single capsule containing aspirin, a statin and two blood pressure-lowering agents)
amongst Indigenous and non-Indigenous people at high risk of experiencing a cardiovascular event will improve
adherence to guideline-indicated therapies, and lower blood pressure and cholesterol levels.
Methods/Design: The study is an open, randomised, controlled, multi-centre trial involving 1000 participants at
high risk of cardiovascular events recruited from mainstream general practices and Aboriginal Medical Services,
followed for an average of 18 months. The participants will be randomised to one of two versions of the polypill,
the version chosen by the treating health professional according to clinical features of the patient, or to usual care.
The primary study outcomes will be changes, from baseline measures, in serum cholesterol and systolic blood
pressure and self-reported current use of aspirin, a statin and at least two blood pressure lowering agents.
Secondary study outcomes include cardiovascular events, renal outcomes, self-reported barriers to indicated
therapy, prescription of indicated therapy, occurrence of serious adverse events and changes in quality-of-life. The
trial will be supplemented by formal economic and process evaluations.
Discussion: The Kanyini-GAP trial will provide new evidence as to whether or not a polypill-based strategy
improves adherence to effective cardiovascular medications amongst individuals in whom these treatments are
indicated.
Trial Registration: This trial is registered with the Australian New Zealand Clinical Trial Registry
ACTRN126080005833347.
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Socioeconomically disadvantaged populations are at high
risk of chronic vascular disease. In Australia, this is par-
ticularly the case for Indigenous peoples, amongst
whom more than one third of the total disease burden
is due to cardiovascular disease (CVD), chronic kidney
disease (CKD) and diabetes[1]. Six risk factors (tobacco,
overweight, high cholesterol, physical inactivity, high
blood pressure, and low fruit and vegetable intake)
explain the majority of this burden[1]. Current national
guidelines for the prevention of cardiovascular events in
people with established athero-thrombotic vascular dis-
ease, or at high risk of these events, recommend - unless
contraindicated - aspirin, Angiotensin Converting
Enzyme (ACE) inhibitors and statin therapy[2-5].
The George Institute for International Health and the
Kanyini Vascular Collaboration (KVC) have recently com-
pleted three cross-sectional studies of CVD risk manage-
ment in Australian general practice and in Aboriginal
Medical Services (AMS) settings[6-8]. The KVC Audit
showed that, amongst a random sample of 1165 Indigen-
ous adults, 40% of patients with established CVD had not
been prescribed the combination of blood pressure (BP)
lowering medicines, statins and antiplatelet agents and
that 56% of high risk individuals without CVD had not
been prescribed BP medicines and statins[7]. Actual
adherence is likely to be even lower. Similar screening and
treatment gaps were found for predominantly non-Indi-
genous adults in mainstream general practices[8] and in
other Australian and international studies[9-14].
The reasons for the current evidence-practice gaps are
likely to be complex. Barriers to adopting guideline
recommendations by doctors might include lack of time,
a confusing multiplicity of guidelines, lack of awareness
of guidelines, and insufficient resources to implement
recommendations[15]. Low adherence to medication is a
well-documented barrier to the continued prevention
and treatment of chronic diseases[16-21]. Non-adher-
ence is associated with taking multiple medicines with
complex dosing regimens, inadequacy of knowledge
about the medications and depression[16,17,20-22]. As
cost is an important contributing factor, patients adopt
strategies to reduce costs - including not filling prescrip-
tions and delaying or omitting doses[20,23]. Aboriginal
people’s inequitable access to medicines subsidised
through the Pharmaceutical Benefits Scheme has been
clearly demonstrated[24].
While the use of a ‘polypill’ for primary prevention in
a population-based approach among people at low risk
remains controversial[25], the potential role of fixed-
dose combination therapy in secondary prevention
amongst people suffering from CVD, or who are at high
risk of such events, has gained wider acceptance
[19,26,27]. A systematic review of randomised trials
comparing the effects of combined packaging of pills or
fixed-dose combination pills with access to the same
medications presented as separate pills, demonstrated
improvements in adherence and in clinical outcomes in
11 of 14 included studies[28]. However, most of the
included studies were of poor methodological quality,
and only three, in the setting of communicable diseases,
examine fixed-dose combination pills.
Is there a potential role for fixed-dose combination
therapy in reducing the treatment gap for patients at
high risk of CVD? To address this question, a rando-
mised controlled trial will be conducted to determine
whether a polypill-based strategy for both Indigenous
and non-Indigenous peoples at high risk of a cardiovas-
cular event will result in better adherence to indicated
therapies, and thus lower blood pressure and serum
cholesterol levels, when compared with usual care. This
will be supplemented by an economic evaluation of the
cost-effectiveness of this strategy within partner Aborigi-
nal Medical Services and mainstream General Practices
and by a process evaluation to explore the underlying
reasons why this strategy might, or might not, be more
effective than standard care in different settings.
Methods & Design
This study is a prospective, open, randomised clinical
trial of a polypill-based strategy compared with usual
care among Indigenous and non-Indigenous Australians
at high CVD risk (Figure 1).
Subjects
The trial will include 1000 participants with either a
previous history of athero-thrombotic vascular disease
or who have a 5-year calculated CVD risk of 15% or
higher. Patients will be recruited from KVC partner
Aboriginal Medical Services (AMS) partners and main-
stream general practices. Participants will be eligible for
the trial if they are aged 18 years or over and able to
give informed consent, have a history of coronary heart
disease (myocardial infarction, stable or unstable angina
pectoris, or coronary revascularization procedure), and/
or ischaemic cerebrovascular disease, and/or peripheral
vascular disease; or a calculated 5-year CVD risk of 15%
or greater. Five-year CVD risk will be calculated using
the 1991 Anderson Framingham risk equation[29].
Adjustments to the estimated risk defined by the New
Zealand Guideline Group recommendations, including a
5% increase for being of Indigenous background, will be
made[5]. For a participant to be eligible, the responsible
medical practitioner should believe that each of the
polypill components are indicated and could be pre-
scribed under the Pharmaceuticals Benefit Scheme.
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contraindication to any of the components of the poly-
pill or if the responsible clinician feels that a change in
current therapy will place the patient at risk. Final deci-
sions about eligibility will be made by the clinician and
the potential study participant.
Randomisation
This will be conducted through a central, computer-
based randomisation service, and will be stratified by
study centre, indication (i.e. previous CVD vs. ≥15% 5-
year CVD risk), and prescription of all appropriate
therapies at baseline (yes vs. no).
Study Treatment
Participants will be randomised to either usual care or
to a polypill-based strategy. For participants randomised
to continue their usual care, management will be at the
discretion of their General Practitioner, who will be
encouraged to provide care consistent with current
guidelines. For those randomised to the polypill-based
strategy, the participant will be prescribed one of two
polypill formulations, at the discretion of the treating
clinician, to be taken orally once daily. Each version
contains two blood-pressure lowering drugs, a statin
and low-dose aspirin. Suggested indications for each for-
mulation are shown in Table 1. The polypill formula-
t i o n su s e di nt h i ss t u d yh a v eb e e nd e v e l o p e da n d
provided free of charge by Dr Reddy’s Laboratories,
Hyderabad, India.
For patients starting these medications for the first
time, the clinician will be able to titrate with low doses
of medications that make up the polypill. For patients
currently taking existing drugs of these classes, medica-
tions will be reduced or discontinued, aiming to main-
tain existing levels of treatment. During follow-up, use
of ‘add on’ therapy in patients randomised to the poly-
pill-based strategy is unrestricted, at the discretion of
the clinician.
In this “real world” implementation trial, the provision
of the study treatment aims to mimic the normal pre-
scribing and dispensing environment. Participants ran-
domised to the polypill-based strategy will obtain their
study drug in accordance with the standard prescribing
and dispensing procedures at each health service. This
will vary and might be dispensed on-site (especially at
remote clinics) or at a pharmacy. Participating pharma-
cies will be registered and will dispense the polypill on
Figure 1 Study Schema.
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gator. As treatment cost might be an important determi-
nant of adherence, it is important that out-of-pocket
expenses for the polypill accord with the pricing envir-
onment for accessing medications in each health service.
Participants randomized to the polypill will pay the
same copayment for a polypills c r i p ta st h e yw o u l df o r
any other medication. Participants randomised to usual
care will continue to fill prescriptions for cardiovascular
medications according to their usual custom.
Follow Up
The average follow-up period will be 18 months.
Because this is a pragmatic study evaluating strategies of
care (rather than therapeutic agents), an open design is
necessary. Appropriate care will be taken to ensure stan-
dardised, and where feasible, blinded, outcome evalua-
tion –“ PROBE” design[30]. During follow-up, all study
participants will attend clinic visits for randomisation, at
12 months, 24 months (if applicable) and at the end of
the study. Research staff will telephone or visit study
participants (especially in remote settings) at 6 months
and 18 months. All other routine visits to the general
practitioner will be at the discretion of that clinician
and the patient.
Outcomes
The primary study outcomes will be changes, from base-
line measures, in serum cholesterol and systolic blood
pressure and self-reported current use of aspirin, a statin
and at least two blood pressure lowering drugs. This will
capture the combined effect of changes by the health-
care provider (prescription) and by the patient (adher-
ence). The use of biological markers (i.e. levels of blood
pressure and cholesterol) directly measure the conse-
quences of changes in adherence, and translate directly
to likely improvements in hard clinical outcomes. The
secondary outcomes of the trial include cardiovascular
events, renal outcomes, self-reported barriers to
indicated therapy, prescription of indicated therapy,
occurrence of serious adverse events, and quality-of-life.
Statistical considerations
Assumptions regarding differences in adherence to
guideline-indicated therapies are based on evidence
from the recent audits of CVD management in both
Indigenous and mainstream primary care settings[6-8].
The following assumptions inform sample size estimates:
(i) there is 35% baseline adherence to all components of
the polypill (i.e. aspirin, statin and at least 2 blood pres-
sure-lowering agents); (ii) adherence to all components
of the polypill among participants randomised to “usual
care” over the duration of the trial will increase to 50%;
and (iii) 80% of participants randomised to the polypill-
based strategy will remain adherent to the polypill dur-
ing follow-up (allowing for 20% drop-out from therapy
during follow-up).
Allowing for 10% deaths and loss to follow-up, rando-
misation of 1000 participants will provide 90% power at
a two-sided 0.05 significance level to detect at least a 3
mmHg difference in systolic blood pressure, and at least
0.20 mmol/L difference in serum cholesterol. This
assumes that the standard deviations around the base-
lines for these variables are 14 mmHg and 0.9 mmol/L
respectively. This study is underpowered to detect plau-
sible differences in cardiovascular events, but the data
from Kanyini GAP will contribute to a prospective
meta-analysis including other international polypill trials
with similar protocols. All analyses will be performed on
an intention-to-treat basis. An independent Data and
Safety Monitoring Committee will be established to
review unblinded interim data on efficacy and safety.
Economic evaluation of the Polypill-based strategy
A cost-effectiveness analysis, taking a health system per-
spective, will compare the polypill-based strategy with
usual care. This will entail a trial-based economic eva-
luation and a modelled economic evaluation of long-
term costs and outcomes. In the trial based economic
evaluation, the costs of medications, based on actual
market prices for each item and a range of indicative
prices for the polypill, will be compared between the
two groups (including follow-up of patients who fail to
adhere to allocated treatment). Costs of other medica-
tions, laboratory tests and medical consultations will be
extracted from Medicare and Pharmaceutical Benefits
Scheme (PBS) records and costed at prevailing rates.
Hospitalisations will be recorded routinely as serious
adverse events in the trial and will be costed using stan-
dard Australian National Diagnosis Related Groups
(AN-DRG) cost weights. In addition, the measures of
self-reported health based on the EQ 5 D administered
at baseline, 12 months and the final visit will enable
Table 1 Formulations of polypill available for
prescription, and recommended indications
Clinical history Intervention group
Coronary heart disease Formulation 1*
Cerebrovascular disease Formulation 2**
Both or other athero-thrombotic vascular
disease
Either Formulation 1* or
2**
>15% 5-year CVD risk, but without
established CVD
Formulation 2**
*Polypill with aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, atenolol 50
mg
**Polypill with aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg,
hydrochlorothiazide 12.5 mg
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promoting access to care, out-of-pocket costs will be
compared between the two groups as a separate analysis.
These will include patient co-payments associated with
medications and with medical consultations. The trial-
based economic evaluation will estimate the incremental
cost consequences of the polypill strategy in achieving
each of the primary outcomes and will estimate the
incremental cost per Quality Adjusted Life Year (QALY)
at 18 months.
A modelled economic evaluation will be done, using a
state transition or Markov model, to capture costs and
outcomes which occur beyond the period of the trial.
This will enable quality of life and survival to be exam-
ined beyond the 18-month follow-up. Using the Markov
model, patients in usual care and the polypill-based
strategy would be tracked over an extended period to
capture various health states. Transition from good
health to major morbidity (for example stroke), or mor-
tality, will be based on probabilities related to the long-
term effects of blood pressure and cholesterol lowering,
and anti-platelet therapy, medication safety and disease
progression, derived from the trial findings and litera-
ture review. Costs and quality of life attached to various
states of health will be based on findings from the trial.
With appropriate discounting, estimates of long-term
costs and outcomes will be derived from the model.
Sensitivity analyses will be conducted on the discount
rate, uncertainty in outcome estimates and assumptions
made in the costings. In addition, given that the market
price for the polypill is yet to be established, different
pricing scenarios will be tested to determine the thresh-
old values for achieving cost-effectiveness.
Process evaluation of the Polypill-based Strategy
A process evaluation will explore the barriers and
enablers to implementing a polypill-based strategy to
enhance prescriber and consumer adherence to the indi-
cated therapies[32]. This will inform the interpretation
of the key findings of the trial, considerations regarding
transferability of the results to other settings, and will
assist in translating findings into policy and practice[33].
Mid-way through follow-up, semi-structured interviews
will be conducted with key prescribers and other staff in
participating AMSs and mainstream general practices.
We aim to explore their views on the advantages, disad-
vantages, acceptability and applicability of the polypill
strategy along with their accounts of how participation
in the study itself changed their prescribing behaviour.
At the end of follow-up, selected patients will be inter-
viewed to explore their views on the benefits, disadvan-
tages and acceptability of the polypill. Recruitment of
staff and patients for interviews will be purposive, to
maximise variation according to criteria including
location, service size, role and degree of participation
(for staff); and location, sex, age and outcomes (for
patients). Analysis of the interview data will be primarily
thematic[34] and will be informed by the realistic eva-
luation model of Pawson and Tilley[35], which seeks to
understand human choices, actions and attitudes, within
the context of the systems in which these players
operate.
A multi-disciplinary team, comprised of Indigenous
and non-Indigenous, clinical and non-clinical research
staff, will undertake the analysis to ensure that its inter-
pretation is sensitive to different perspectives. Using the
constant comparative method [36], analyses will occur
concurrently with interviews and themes will be conti-
nually modified by the team in the light of additional
data. NVivo (QSR International, Melbourne, Victoria)
will be used to assist with data management. This soft-
ware is particularly useful when there are multiple
coders across several sites, allowing us to bring local,
context-rich analyses to interpretation of the findings.
Study organisation and Timelines
The study will be centrally managed by The George
Institute, with the design and conduct overseen by a
Steering Committee. Regional management of study
centres will be the responsibility of the George Institute
(Sydney-based), the Baker IDI Centre for Indigenous
Vascular & Diabetes Research (Alice Springs-based) and
Monash University (Melbourne-based). Ethics approval
was first granted by Sydney South West Area Health
Service Human Research Ethics Committee (HREC)
(RPAH zone), and subsequently by relevant HRECs
across the country which are the Aboriginal Health &
Medical Research Council HREC, Cairns and Hinterland
Health Service District HREC, Central Australian HREC,
Metro South Health Service District HREC and Monash
University HREC. Participant recruitment commenced
in December 2009 and should be completed by July
2011. Follow-up will continue until December 2012.
Process evaluation interviews will occur mid-trial and at
the end of follow-up. The economic evaluation, includ-
ing data collection and modelling, will occur through-
out. Publication of final results is planned for early 2013.
Discussion
This clinical trial is one study within the KVC health
services research program. In 2006, with funding from a
national, competitive, peer-reviewed grant, KVC aimed
to explore barriers and facilitators to the delivery of
high quality care and to develop culturally appropriate,
innovative and accessible models of care. KVC’s achieve-
ments include an audit of the detection, prevention and
management of chronic vascular diseases[7] and a quali-
tative study exploring barriers to improving health
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together researchers, health service providers and
research institutes across Indigenous and mainstream
health sectors to undertake a clinical trial, economic
and process evaluations. We believe that working across
this apparent health sector divide, will strengthen our
ability to change health service provision to improve
population health.
This clinical trial component has an ambitious recruit-
ment period of 18 months, which might be a challenge for
both AMSs and mainstream primary care settings. Rea-
sons include a generally negative perception of research in
many Indigenous communities[37-39], the considerable
length of time required for consultation with communities
to form research partnerships[38,40] and the practicalities
of conducting clinical trials in busy AMSs and primary
health care settings within the limitations of non-commer-
cial research funding[41,42]. The initial consultations with
partner AMSs have set the research agenda and the
strength of our partnerships will be fundamental to suc-
cessfully implementing the trial across remote, rural and
urban settings within the intended time-frame.
This clinical trial is consistent with KVC’s core objective
to build the capacity of community members and health
services to conduct rigorous, high-quality research and to
develop, implement and evaluate interventions to address
barriers to care. The research capacity of the Indigenous
workforce is enhanced through the employment, support
and training of Indigenous Research Fellows (IRFs) based
at our partner AMSs. KVC directly supports the IRFs in
their conduct of the study through regular face-to-face
and teleconference meetings, supports attendance at
research courses and encourages the use of research find-
ings to satisfy post-graduate course requirements. This
support, provided in collaboration with each IRF’s employ-
ing health service, has sustained the development of Indi-
genous researchers within a culturally and academically
safe environment. KVC has benefitted from this reciprocal
capacity-building process, whereby Indigenous attitudes
and community priorities have been promoted to non-
Indigenous researchers to ensure appropriate cross-cul-
tural communication and accountability in the analysis
and dissemination of findings.
The Kanyini-GAP study team aims to generate robust
evidence to persuade governments to change policy.
Having demonstrated systemic evidence-practice gaps
across AMS and mainstream primary care sectors, we
believe a polypill-based strategy for people at high cardi-
ovascular risk might address these gaps, especially
amongst disadvantaged populations. In addition, through
partnership with AMS and mainstream primary care
services, we aim for greater generalisability of trial
results. In this manner we hope to contribute to sus-
tained improvements in health for all Australians.
Acknowledgements
The Kanyini GAP Study is an investigator-initiated and conducted study,
funded by a primary health care project grant (#457508), a health services
program grant (#402797) and a project grant (#632810) from the Australian
National Health & Medical Research Council (NHMRC). AC and AP are funded
by Senior Research Fellowships from the NHMRC. AB is funded by an
Indigenous post-doctoral fellowship from the National Heart Foundation. SJ
is funded by an NHMRC Career Development Award. We thank Dr Peter
Arnold for his assistance in the preparation of this paper.
Collaborators
Kanyini GAP Steering Committee:
Anushka Patel (Chair)
Alan Cass
Alex Brown
David Peiris
Christopher Reid
Stephen Jan
Noel Hayman
Susan Thomas
Hugh Burke
Anthony Rodgers
Andrew Tonkin
Tim Usherwood
David Henry
Patrick Groenestein
Natasha Rafter
Bruce Neal
Graham Hillis
Barbara Molanus
Hueiming Liu
Bindu Patel
Kanyini GAP Data and Safety Monitoring Committee:
John Simes
Mark Harris
Warren Walsh
Kanyini GAP Clinical Endpoints Adjudication Committee:
Neil Chapman
Ajay Gupta
Clara Chow
Michele McGrady
S Harikrishnan
Kanyini Vascular Collaboration:
Chief Investigators: Alan Cass, Anushka Patel, Alex Brown, Sandra Eades,
Noel Hayman, Nicole Isbel, Stephen Jan, Ian Ring, Greg Stewart, Andrew
Tonkin, Tarun Weeramanthri, Vicki Wade.
Kanyini GAP Project Staff:
TGI: Bindu Patel, Robyn Walsh, Maria Tchan, Deborah Blair, Evelyn Nangle,
Jennifer Hibbard, Katy Powell, Tracey Laba
Baker IDI: Barbara Molanus, Emma Tilley, Anita Curtis, Helen Liddle,
Bernadette Rickards, Samantha Togni
Monash University: Louise Shiel, Kathleen White, Caroline Steer
Partner Aboriginal Medical Services and their Principal Investigators/
Research Nurse/Indigenous Research Fellows:
Aboriginal Medical Service Western Sydney, Mt Druitt, NSW - Penny Abbott,
Sonya Cameron, Jenny Reath
Central Australian Aboriginal Congress, Alice Springs NT
Inala Indigenous Health Service, Brisbane, QLD - Noel Hayman, John Brady,
Michelle Bowles
Maari Ma Health Aboriginal Corporation, Broken Hill, NSW - Vic Carroll, Maria
Tattersall
Nganampa Health Council, SA- Peter Bennett, Martin Kelly, Kerrie Gell, Paul
Torzillo
Tharawal Aboriginal Corporation, Campbelltown, NSW- Tim Senior, Vicki
Colloney, Urapuntja Health Service, Utopia NT- Karmananda Saraswati
Western Aranda Health Aboriginal Corporation NT - Peter Fitzpatrick
Wuchopperen Health Service, QLD,- Sharmila Biswas, Joanne De Vries, Barry
Fewquandie
Mainstream General Practices:
Inala Primary Care, QLD - Suzanne Williams
Hazelbrook General Practice, NSW - Louise McDonnell
Upper Mountains Medical Centre, NSW - Andrew Knight
Liu et al. BMC Public Health 2010, 10:458
http://www.biomedcentral.com/1471-2458/10/458
Page 6 of 8Castle Hill Medical Practice, NSW - Bob Elliott
Tindale Family Practice, NSW - Steven Wong
Narromine Shire Family Health Centre, NSW - William Dean Wright
Select Medical group, VIC - Irmgard Chia
Medical Centre, VIC - Nigel Rosen
Lesdon Ave Medical Centre, VIC - Dr Stephen Ward
Dandenong Medical Centre, VIC - Jim Demirtzoglou
Seaford Beach Family Clinic, VIC - Adel Botrous
Mount Martha Village Clinic, VIC - Mark Sujecki
Langton Medical Centre, VIC- John Meaney
Author details
1The George Institute for International Health, PO Box M201, Missenden
Road, NSW 2050, Australia.
2Baker IDI Centre for Indigenous Vascular &
Diabetes Research PO Box 1294, Alice Springs, Northern Territory 0871,
Australia.
3Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road
Central, Victoria 8008, Australia.
4Inala Indigenous Health Service, 64
Wirraway Pde, INALA, QLD, 4077, Australia.
5University of Wollongong,
Northfields Ave, Wollongong NSW 2500, Australia.
6Sydney South West Area
Health Service, Eastern Campus Of Liverpool Hospital Elizabeth St, Liverpool
NSW 2170, Australia.
7Monash University, Victoria 3800 Australia.
8WA Health,
Level 3, B Block, 189 Royal Street, East Perth WA 6004, Australia.
9The
University of Sydney, PO Box 154, Westmead, NSW 2145. Australia.
10Maari
Ma Aboriginal Corporation, 443 Argent Street, PO Box 339 Broken Hill, NSW,
2880, Australia.
Authors’ contributions
The writing group of this manuscript are members of the Kanyini Vascular
Collaboration and Kanyini GAP study team. Different members of the writing
group have contributed significantly to writing and manuscript revision,
study design, securing of funding, stake holder engagement, ethics approval
and oversight of study implementation and the study implementation at
sites. The writing group comprise of HL, AP, AB, SE, NH, SJ, IR, GS, AT, TW,
VW, AR, TU, BN, DP, HB, CR and AC. All authors read and approved the final
manuscript.
Competing interests
Anushka Patel, David Peiris and Alan Cass received reimbursements for travel
and accommodation funded by Doctor Reddy’s Laboratory, Hyderbad, India
to attend international Polypill collaborative meetings. Other author(s)
declare that they have no competing interests.
Received: 9 July 2010 Accepted: 5 August 2010
Published: 5 August 2010
References
1. Vos T, Barker B, Stanley L, Lopez A: The burden of disease and injury in
Aboriginal and Torres Strait Islander peoples 2003. Brisbane: The
University of Queensland 2007.
2. National Heart Foundation of Australia, Cardiac Society of Australia and
New Zealand: Reducing risk in heart disease 2004 National Heart Foundation
of Australia 2005.
3. National Heart Foundation of Australia: Hypertension management guide for
doctors National Heart Foundation 2004.
4. National Stroke Foundation: Clinical guidelines for the management of acute
stroke National Stroke Foundation 2002.
5. New Zealand Guidelines Group: New Zealand Cardiovascular Guidelines
Handbook: A summary resource for primary care practitioners.
Wellington: New Zealand Guidelines Group, 2 2009.
6. Heeley EL, Peiris DP, Patel AA, Cass A, Weekes A, Morgan C, Anderson CS,
Chalmers JP: Cardiovascular risk perception and evidence–practice gaps
in Australian general practice (the AusHEART study). Med J Aust 2010,
192(5):254-259.
7. Peiris DP, Patel AA, Cass A, Howard MP, Tchan ML, Brady JP, De Vries J,
Rickards BA, Yarnold DJ, Hayman NE, Brown ADH: Cardiovascular disease
risk management for Aboriginal and Torres Strait Islander peoples in
primary health care settings: findings from the Kanyini Audit. Med J Aust
2009, 191(6):304-309.
8. Webster RJ, Heeley EL, Peiris DP, Bayram C, Cass A, Patel AA: Gaps in
cardiovascular disease risk management in Australian general practice.
Med J Aust 2009, 191(6):324-329.
9. Brady AJ, Oliver MA, Pittard JB: Secondary prevention in 24, 431 patients
with coronary heart disease: survey in primary care. BMJ 2001,
322(7300):1463..
10. Peiris D, Murray J, Scully D, Tilakawardene V, Hetaraka-Stevens L, Stewart T,
Patel A: Cardiovascular risk management at a Maori-led Primary Health
Organisation–findings from a cross-sectional audit. NZM e dJ2008,
121(1285):35-46.
11. Rafter N, Wells S, Stewart A, Selak V, Whittaker R, Bramley D, Roseman P,
Furness S, Jackson RT: Gaps in primary care documentation of
cardiovascular risk factors. NZM e dJ2008, 121(1269):24-33.
12. Reid C, Nelson MR, Shiel L, Chew D, Connor G, DeLooze F: Australians at
risk: management of cardiovascular risk factors in the REACH Registry.
Heart Lung Circ 2008, 17(2):114-118.
13. Steven ID, Wing L: Control and cardiovascular risk factors of
hypertension. An assessment of a sample of patients. Aust Fam Physician
1999, 28(1):45-48.
14. Vale MJ, Jelinek MV, Best JD: How many patients with coronary heart
disease are not achieving their risk-factor targets? Experience in Victoria
1996-1998 versus 1999-2000. Med J Aust 2002, 176(5):211-215.
15. Grol R, Grimshaw J: From best evidence to best practice: effective
implementation of change in patients’ care. Lancet 2003,
362(9391):1225-1230.
16. Bailey JE, Lee MD, Somes GW, Graham RL: Risk factors for antihypertensive
medication refill failure by patients under Medicaid managed care. Clin
Ther 1996, 18(6):1252-1262.
17. Barat I, Andreasen F, Damsgaard EM: Drug therapy in the elderly: what
doctors believe and patients actually do. Br J Clin Pharmacol 2001,
51(6):615-622.
18. Davis M: Current targets: where are we going? Heart 2003, 89(Suppl 2):
ii6-9, discussion ii35-37.
19. Gupta AK, Arshad S, Poulter NR: Compliance, safety, and effectiveness of
fixed-dose combinations of antihypertensive agents: a meta-analysis.
Hypertension 2010, 55(2):399-407.
20. Houston Miller N, Hill M, Kottke T, Ockene IS: The Multilevel Compliance
Challenge: Recommendations for a Call to Action. A Statement for
Healthcare Professionals. Circulation 1997, 95(4):1085-1090.
21. Paes AH, Bakker A, Soe-Agnie CJ: Impact of dosage frequency on patient
compliance. Diabetes Care 1997, 20(10):1512-1517.
22. Rieckmann N, Gerin W, Kronish IM, Burg MM, Chaplin WF, Kong G,
Lesperance F, Davidson KW: Course of depressive symptoms and
medication adherence after acute coronary syndromes: an electronic
medication monitoring study. J Am Coll Cardiol 2006, 48(11):2218-2222.
23. Shaw E, Anderson JG, Maloney M, Jay SJ, Fagan D: Factors associated with
noncompliance of patients taking antihypertensive medications. Hosp
Pharm 1995, 30(3):201-203, 206-207.
24. Australian Institute of Health and Welfare: Expenditures on health for
Aboriginal and Torrres Strait Islander peoples, 2004-05. Volume Cat. No. HWE
40 Canberra: Australian Institute of Health and Welfare 2008.
25. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more
than 80%. BMJ 2003, 326(7404):1419.
26. World Health Organisation: Secondary prevention of non-communicable
disease in low and middle income countries through community-based
and health service interventions. World Health Organisation - Wellcome
Trust Meeting Report 1-3 August 2001, Geneva. Geneva: World Health
Organisation 2002.
27. Yusuf S: Two decades of progress in preventing vascular disease. Lancet
2002, 360(9326):2-3.
28. Connor J, Rafter N, Rodgers A: Do fixed-dose combination pills or unit-of-
use packaging improve adherence? A systematic review. Bull World
Health Organ 2004, 82(12):935-939.
29. Anderson KM, Odell PM, Wilson PW, Kannel WB: Cardiovascular disease
risk profiles. Am Heart J 1991, 121(1 Pt 2):293-298.
30. Hansson L, Hedner T, Dahlof B: Prospective randomized open blinded
end-point (PROBE) study. A novel design for intervention trials.
Prospective Randomized Open Blinded End-Point. Blood Press 1992,
1(2):113-119.
31. EuroQol Group: EuroQol–a new facility for the measurement of health-
related quality of life. The EuroQol Group. Health Policy 1990,
16(3):199-208.
Liu et al. BMC Public Health 2010, 10:458
http://www.biomedcentral.com/1471-2458/10/458
Page 7 of 832. Oakley A, Strange V, Bonell C, Allen E, Stephenson J: Process evaluation in
randomised controlled trials of complex interventions. BMJ 2006,
332(7538):413-416.
33. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P,
Spiegelhalter D, Tyrer P: Framework for design and evaluation of complex
interventions to improve health. BMJ 2000, 321(7262):694-696.
34. Patton M: Qualitative research and evaluation methods. Thousand Oaks:
Sage 2002.
35. Pawson R, Tilley N: Realistic evaluation London; Thousand Oaks, Calif.: Sage
1997.
36. Glaser BG, Strauss AL: The discovery of grounded theory: strategies for
qualitative research. Chicago: Aldine 1967.
37. Atkinson VJ, Graham J, Pettit G, Lewis L: Broadening the focus of research
into the health of Indigenous Australians. Med J Aust 2002,
177(6):286-287.
38. Couzos S, Lea T, Murray R, Culbong M: ’We are not just participants–we
are in charge’: the NACCHO ear trial and the process for Aboriginal
community-controlled health research. Ethn Health 2005, 10(2):91-111.
39. Humphery K: Dirty questions: Indigenous health and ‘Western research’.
Aust N Z J Public Health 2001, 25(3):197-202.
40. Henderson R, Simmons DS, Bourke L, Muir J: Development of guidelines
for non-indigenous people undertaking research among the indigenous
population of north-east Victoria. Med J Aust 2002, 176(10):482-485.
41. Macaulay AC: Promoting participatory research by family physicians. Ann
Fam Med 2007, 5(6):557-560.
42. Sibthorpe BM, Bailie RS, Brady MA, Ball SA, Sumner-Dodd P, Hall WD: The
demise of a planned randomised controlled trial in an urban Aboriginal
medical service. Med J Aust 2002, 176(6):273-276.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/10/458/prepub
doi:10.1186/1471-2458-10-458
Cite this article as: Liu et al.: Rationale and design of the Kanyini
guidelines adherence with the polypill (Kanyini-GAP) study: a
randomised controlled trial of a polypill-based strategy amongst
Indigenous and non Indigenous people at high cardiovascular risk. BMC
Public Health 2010 10:458.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liu et al. BMC Public Health 2010, 10:458
http://www.biomedcentral.com/1471-2458/10/458
Page 8 of 8